Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks

Page 2 of 15

14. Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

Number of Hedge Fund Holders: 41 

Viking Global’s Stake: $39.5 million  

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is a significant unmet medical need. These factors underscore why the company is a solid investment opportunity. Firstly, as per the report of the third quarter of 2024, Edgewise Therapeutics has demonstrated a robust strategy by securing substantial capital to support its ongoing programs. The $232 million raised in early 2024 provides a solid foundation for advancing muscular dystrophy and cardiovascular initiatives. However, the company’s reliance on the success of its key drug candidates, sevasemten and EDG-7500, underscores the importance of continued positive trial outcomes to maintain investor confidence and drive future revenue streams. Secondly, the company has highlighted progress in its drug pipeline, especially the positive Phase 2 trial results for sevasemten in Becker muscular dystrophy and initial positive results from EDG-7500 in patients with obstructive hypertrophic cardiomyopathy.

Page 2 of 15